ArticleJournal of cellular and molecular medicine2026
Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ovarian cancer (OC) is a type of gynaecological cancer with a higher mortality rate due to diagnosis at an advanced stage and limited treatment options. This study aimed to leverage transcriptomic data to identify cellular and molecular pathways and potential anti-cancer compounds that specifically target primary invasive epithelial ovarian cancer (EOC). By employing next-generation knowledge discovery (NGKD) methodologies, we sought to unravel the intricate molecular landscape of primary invasive EOC using RNA sequencing (RNA-seq) data and decipher potential therapeutics for this debilitating disease. We performed NGKD analysis of the Gene Expression Omnibus (GEO) dataset GSE1295399 obtained from whole RNA-seq experiments. Using the raw counts and filtered metadata from GEO, we identified 2123 differentially expressed genes (DEGs) based on a Log
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.